Detalhe da pesquisa
1.
Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
Int J Urol
; 29(11): 1322-1330, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000794
2.
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Prostate Cancer Prostatic Dis
; 25(4): 741-748, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35091711
3.
Prognostic Significance of Inflammation-associated Blood Cell Markers in Nonmetastatic Clear Cell Renal Cell Carcinoma.
Clin Genitourin Cancer
; 18(4): 304-313, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31892491
4.
Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Prostate Cancer Prostatic Dis
; 25(4): 803, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288663